Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide

<div>The bar chart demonstrating the 1-, 3-, and 5-year survival outcomes for the entire study population and per pan-immune-inflammation value (PIV) groups (PFS: progression-free survival; OS: overall survival; L-PIV: low pan-immune-inflammation value; H-PIV: high pan-immune-inflammation value).</div>

Journal of Immunology Research

fig3

Figure 3

Figure 3: Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide 

Figure 3 | Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide 